Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Takeda explores the potential of ‘digital biomarkers’

Collaborates with Mindstrong Health on mental health research

Takeda

Takeda is exploring the potential of ‘digital biomarkers’ to help develop new mental health treatments, with a particular focus on schizophrenia and treatment-resistant depression.

The firm is collaborating with Mindstrong Health, whose digital phenotyping platform continuously measures brain function from passively collected smartphone data.

Emiliangelo Ratti, head of Takeda’s Neuroscience Therapeutic Area Unit, said: "Mental health disorders are complex, multifaceted conditions, and drug development in this area of unmet need is slow to progress.

"This partnership with Mindstrong Health exemplifies Takeda's motivation to engage in digital technologies to improve the clinical assessment of patients with mental health conditions who lack adequate treatment options."

Dr Paul Dagum, founder and CEO of Mindstrong Health, added: "Takeda shares our goal of using innovative technology to gain insights that will improve outcomes for people living with mental health conditions.

"We are pleased to partner with them to implement digital technology in the clinical development of novel assets and, hopefully, allow for faster delivery of meaningful therapies to patients."

The companies hope that by joining forces they will be able to develop novel therapeutic interventions by applying digital biomarkers to stratify mental health conditions and predict remission.

6th March 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics